Prothena Corp (PRTA) 55.05 $PRTA What's in Store for

New Post Public Reply Private Reply Replies (0) Message Board

Aug 1, 2016 at 3:22 AM

Prothena Corp (PRTA) 55.05 $PRTA

What's in Store for Prothena (PRTA) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 3:44PM CDT
Prothena Corporation plc (PRTA) is expected to report second-quarter 2016 results on Aug 2.
IPXL: 31.42 (-0.05), IRWD: 14.13 (-0.21), PRTA: 55.05 (-0.36), EXEL: 9.18 (+0.23)

Prothena to Participate in Cantor Fitzgerald's 2nd Annual Healthcare Conference
GlobeNewswire - Wed Jul 06, 3:05PM CDT
Prothena Corporation plc (NASDAQ

RTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that members of its senior management team will present and participate in Cantor Fitzgerald's 2nd Annual Healthcare Conference on July 12 at 11:45 AM ET in New York, NY.
PRTA: 55.05 (-0.36)

Prothena Reports Results of Phase 1 Single Ascending Dose Study of PRX003, Demonstrating Target Engagement of the Novel Anti-MCAM Antibody for Inflammatory Diseases
Globe Newswire - Thu Jun 09, 3:05PM CDT
- All doses of PRX003 found to be safe and well tolerated, meeting the primary objective of the Phase 1 single ascending dose study in healthy volunteers
PRTA: 55.05 (-0.36)

Prothena to Present Wide Range of Studies on Amyloidosis, Including New Clinical Data on NEOD001, at International Symposium on Amyloidosis
Globe Newswire - Mon May 23, 3:05PM CDT
- New clinical data to be presented from expansion cohort of Phase 1/2 trial of NEOD001 for the potential treatment of AL amyloidosis
PRTA: 55.05 (-0.36)

Prothena to Present Quality of Life Data on AL Amyloidosis at European Hematology Association 21st Congress
Globe Newswire - Thu May 19, 3:05PM CDT
DUBLIN, Ireland, May 19, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq

RTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that data from multiple quality of life studies in patients with AL amyloidosis will be highlighted at The European Hematology Association (EHA) 21st Congress to be held June 9-12 in Copenhagen, Denmark.
PRTA: 55.05 (-0.36)

Prothena to Present Clinical Results From its Phase 1 Single Ascending Dose Study of PRX003, an Anti-MCAM Antibody Being Investigated for Inflammatory Diseases, at EULAR 2016
Globe Newswire - Mon May 09, 3:05PM CDT
DUBLIN, Ireland, May 09, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq

RTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that clinical data from its Phase 1 single ascending dose study of PRX003 in healthy volunteers will be highlighted in an oral presentation at The European League Against Rheumatism Annual European Congress of Rheumatology (EULAR 2016) to be held June 8-11 in London.
PRTA: 55.05 (-0.36)

Prothena (PRTA) Reports Wider-than-Expected Loss in Q1
Zacks Equity Research - Zacks Investment Research - Wed May 04, 12:00PM CDT
Prothena Corporation plc (PRTA) reported a loss of 81 cents per share in the first quarter of 2016, much wider than both the Zacks Consensus Estimate of a loss of 70 cents.
SHPG: 194.12 (+2.69), PRTA: 55.05 (-0.36), NKTR: 17.29 (+1.19)

Prothena Reports First Quarter 2016 Financial Results and Provides R&D Update
Globe Newswire - Tue May 03, 3:05PM CDT
- Net cash used in operating and investing activities was $25.4 million in the first quarter; strong quarter-end cash position of $474.3 million, including net proceeds of $128.6 million raised through January 2016 public equity offering, supports advancement of multiple clinical development programs
PRTA: 55.05 (-0.36)

Drug Stocks Q1 Earnings Preview: AEGR, AERI, MACK, PRTA
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 8:04AM CDT
The going has been quite satisfactory as we stand in the thick of the first earnings season of the year.
MACK: 5.80 (+0.19), BIIB: 289.93 (+0.90), ABT: 44.75 (+0.30), JNJ: 125.23 (+0.77), AERI: 17.35 (-0.19), AEGR: 1.44 (-0.03), PRTA: 55.05 (-0.36)

Prothena (PRTA): What's Ahead for the Stock in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 5:42PM CDT
Prothena (PRTA) is expected to report first-quarter 2016 earnings on May 3.
ZTS: 50.47 (+0.41), AGIO: 45.23 (+1.37), PRTA: 55.05 (-0.36)

Data from Prothena's Preclinical Program on Conformation-Specific Antibodies Against Misfolded Transthyretin Published in Amyloid
Globe Newswire - Wed Mar 16, 3:05PM CDT
Antibodies bind specifically to misfolded, non-native forms of transthyretin, disrupting fibril formation
PRTA: 55.05 (-0.36)

Data From Prothena's Ongoing Phase 1/2 Clinical Trial of NEOD001 in AL Amyloidosis Published in the Journal of Clinical Oncology
Globe Newswire - Tue Feb 09, 7:10AM CST
Interim Results Previously Presented at Meetings of the American Society for Clinical Oncology and the European Hematology Association
PRTA: 55.05 (-0.36)

Prothena to Report Fourth Quarter and Full Year 2015 Financial Results and Host Webcast Conference Call on February 18
GlobeNewswire - Thu Feb 04, 3:06PM CST
Prothena Corporation plc (Nasdaq

RTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today that it will report its fourth quarter and full year 2015 financial results on Thursday, February 18, 2016, after the close of the U.S. financial markets. The announcement will be followed by a live audio webcast and conference call at 4:30 PM ET.
PRTA: 55.05 (-0.36)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Trial for Former OB/GYN Arthur Park Begins in Bakersfield

A Somber Day for Justice in Bakersfield There’s a buzz in the air, thick with anticipation and grief, as a trial seven years in the making kicks off in Bakersfield. It’s a significant affair, marking a turning point in a saga that’s shadowed the region with untold grief and unresolved accountability. We’re talking about the trial of Arthur Park, a former OB/GYN,...

Partner Valuation Advisors Bolsters Team with Eichman

Eichman Joins Partner Valuation Advisors as MD Turns out the buzz in real estate appraisal isn’t just about property values these days; it's about who's valuing them. Just ask Partner Valuation Advisors, who are realigning their chess pieces by bringing seasoned pro Justin Eichman, MAI, on board as Managing Director. Talk about playing your cards right. A Heavyweight in...

Home Buying: Unmasking All the Real Budget Costs

Home Buying: More Costs Than Meets the Eye Let's face it, buying a home is no stroll in the park. It's a tangled web of numbers and surprises that can leave even the savviest buyer in a daze. Thank goodness for articles like the one from HelloNation featuring Serena LoPiccolo-Smith, which make the invisible visible when it comes to the financial intricacies of home...

Montessori and Tech: A New Era of Integration

Reimagining Montessori with Technology Let's take a stroll down the road less traveled—the intersection of Montessori education and tech. For over a century, Montessori schools have valued individual child development, autonomy, and a purpose-driven environment. But let's face it, their technology hasn't always had the same handcrafted finesse. That's where illumine...

Quark Baby's Milk Warmer Debut at Vancouver & Dubai

An Unconventional Pitch for Baby Gear Quark Baby is strutting its stuff not just in Vancouver but all the way in Dubai. Yeah, we're talking about a milk warmer hitting two major expos. What's the deal with an award-winning brand from Vancouver making so much noise? From October 17-18, they're home-court at The Baby Show Vancouver, and by October 22-24, they're in Dubai at...

OmniActive's Fenavari: A New Era in Women's Health

Pioneering Women's Health with Fenavari You ever wonder why some health products get all the hype? Here's one for the book: OmniActive Health Technologies launching Fenavari, their top-tier contender in the women's health market. Now, we're not talking your run-of-the-mill supplement here. We're stepping onto a new playing field, especially with Dr. Taz Bhatia stepping...

Montesodi 2023: A Fresh Chapter in Chianti Excellence

A Glass Filled with History and Nature's Whimsy When you pour a glass of Montesodi 2023, you’re not just tasting wine but a story—a saga that blends Tuscany’s rich vineyard history with last year's unpredictable weather. Marchesi Frescobaldi, a name that’s seen it all over its thousand years, has once again shown us how resilience and tradition can marry with...

Navigating Battery Compliance for AI Data Centers

Untangling the Web of Global Battery Compliance Amid clamor about AI's insatiable appetite for energy storage, the rules around shipping, installing, and handling data center batteries have become a tangled web. From Waxahachie, Texas, Americase International plans to take the stage at the OCP Global Summit on October 15, 2026, to spearhead a discussion on bridging the...

Canada and Ukraine Fortify Defense with UGV Partnership

New Defense Fronts: Canada and Ukraine Join Forces October 13, 2026, marks an important day in Ottawa's defense narrative with Dominion Dynamics and Ukraine's TENCORE kicking off a robust partnership. They're not just collaborating; they're plugging into each other's strengths to build TerMIT uncrewed ground vehicles (UGVs) on Canadian soil. These aren't gizmos you find...

Fluence Energy Faces Major Lawsuit Amid $3B Loss

Securities Class Action: A Storm Brewing Just when you think you've got a grip on the market, a sharp right hook can come out of nowhere. Fluence Energy (NASDAQ:FLNC) is dealing with one of those punches now, getting dragged into the courtroom over claims they fudged financial lines. They hail innovation in energy storage, but shareholders are left shaking in their boots...